We Claim:

1. (Original) Amorphous rosuvastatin magnesium.

2. (Original) Amorphous rosuvastatin magnesium having purity greater than 99% with diastereomeric impurity less than 0.5%.

3. (Original) Amorphous rosuvastatin magnesium according to claim 2 having purity greater than 99.5% with diastereomeric impurity less than 0.25%.

4. (Original) Amorphous rosuvastatin magnesium according to claim 3 having purity greater than 99.8% with diastereomeric impurity less than 0.15%.

5. (Original) Amorphous rosuvastatin magnesium substantially free of crystalline rosuvastatin magnesium.

6. (Original) A process for the preparation of crystalline rosuvastatin magnesium comprising:

   a) treating rosuvastatin methyl ammonium salt or rosuvastatin lactone with a base and magnesium salt; and

   b) isolating crystalline rosuvastatin magnesium from the reaction mass.

7. (Cancelled)

8. (Cancelled)

9. (Original) A process for preparing amorphous rosuvastatin magnesium comprising:

   a) dissolving crystalline rosuvastatin magnesium in a first organic solvent;

   b) adding a second organic solvent to the solution of rosuvastatin magnesium or adding the solution of rosuvastatin magnesium to the second organic solvent (in optional order of succession) wherein rosuvastatin magnesium is insoluble or very slightly soluble or sparingly soluble in the second solvent, such that amorphous rosuvastatin magnesium precipitates; and

c) isolating amorphous rosuvastatin magnesium.

10. (Original) A process for preparing amorphous rosuvastatin magnesium comprising:

a) dissolving crystalline rosuvastatin magnesium in an organic solvent;

b) adding water to the solution of rosuvastatin magnesium, or adding the solution of rosuvastatin magnesium to water (in optional order of succession), such that rosuvastatin magnesium precipitates; and

c) isolating amorphous rosuvastatin magnesium.

11. (Cancelled)

12. (Original) A process for preparing amorphous rosuvastatin magnesium comprising:

a) dissolving crystalline rosuvastatin magnesium in an organic solvent optionally containing water; and

b) freeze drying or lyophilizing the solution to get amorphous rosuvastatin magnesium.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Original) A process for preparing rosuvastatin calcium comprising:

a) treating amorphous rosuvastatin magnesium with a base and a calcium salt; and

b) isolating rosuvastatin calcium from the reaction mass.

17. (Cancelled)

18. (Original) Pharmaceutical composition to be used as HMG-CoA reductase inhibitor in treatment of hyperlipidemia comprising amorphous rosuvastatin magnesium.

19. (Original) A method for inhibiting HMG-CoA enzyme in treatment of hyperlipidemia, comprising administering to a mammal in need thereof a therapeutically effective amount of amorphous rosuvastatin magnesium.